Fig 1: Dysregulation of ZNF710-AS1-202 causes significant changes in ZNF710 expression at both the mRNA and protein levels. (A) Schematic of the lncRNA-ZNF710-AS1 (green) and ZNF710-201 transcript (yellow) from ENSEMBL. The levels of ZNF710 expression in RCC cells was detected by (B) reverse transcription-qPCR or (C) western blotting following ZNF710-AS1-202 overexpression. The levels of ZNF710 expression in RCC cells was detected by (D) reverse transcription-qPCR or (E) western blotting ZNF710-AS1-202 suppression. (F) The levels of the ZNF710-201 transcript in different pathological grade ccRCC tissue samples obtained from TCGA (from GPEIA). (G) Overall survival and (H) disease free survival of patients with ccRCC in TCGA according to ZNF710-201 expression (from GPEIA). (I) The expression levels of ZNF710-AS1-201 in RCC cells following ZNF710-AS1-202 overexpression. (J) Overall survival of patients with ccRCC in TCGA according to ZNF710-AS1-201 transcript expression (from GPEIA). (K) Model of ZNF710-AS1-202-dependent regulation of ZNF710 mRNA and protein. In the nucleus of RCC cells, ZNF710-AS1-202 tethered to the fourth intron of ZNF710 pre-mRNA and formed complimentary strands that inhibited ZNF710-201 pre-mRNA splicing. In the cytoplasm, ZNF710-AS1-202 induced the expression of ZNF710 protein. **P<0.01 and ***P<0.001 vs. corresponding pc-NC or SiNC. ZNF710, zinc finger protein 710; TCGA, The Cancer Genome Atlas; ccRCC, clear cell renal cell carcinoma; GEPIA, Gene Expression Profiling Interactive Analysis; lnc, long noncoding; OD, optical density; ns, not significant; siNC, small interfering negative control.